GWA – Macquarie rates the stock as Outperform
Outperform retained. Target is raised to $3.30 from $3.25.
Read MoreBroker News
RMD – Morgans rates the stock as Add
The broker retains its Add rating and reduces its target price to $40.80 from $41.34.
Read MoreMQG – Morgans rates the stock as Hold
Morgans raises its target price to $200 from $181.1 due to a lift in long-term growth assumptions and a valuation adjustment. The Hold rating is unchanged after a strong recent share price rally.
Read MoreRMD – Citi rates the stock as Neutral
The broker retains its Neutral rating and $36.50 target price.
Read MoreANZ – Macquarie rates the stock as Outperform
Outperform retained, target rises to $30.00 from $29.50.
Read MoreCOL – UBS rates the stock as Sell
Negative view on food retailing forms the basis as to why both main players in the sector are now rated Sell. UBS also notes Woolworths supermarkets continue to outperform. Target $16.50.
Read MoreCTD – Morgans rates the stock as Add
Forecasts and the Add rating are left unchanged and the target price to $$27.36 from $25.25.
Read MoreCRN – Morgans rates the stock as Add
The broker lifts its target price to $1.63 from $1.21. Were debt funding terms not complicating the ability to pay dividends, Macquarie believes Coronado’s shares would be trading much higher. Add rating maintained.
Read MoreSLK – Macquarie rates the stock as Neutral
The broker retains a Neutral rating on valuation and $7.85 target price.
Read MoreGOZ – Credit Suisse rates the stock as Neutral
Target price inches up 1c to $4.22 from $4.21. Neutral rating retained.
Read MoreCDA – Macquarie rates the stock as Outperform
Macquarie reduces the target to $15.20 from $17.50 to reflect a lower organic growth outlook in the core detection business. Outperform maintained.
Read MoreACL – Citi rates the stock as Neutral
The broker raises its target price to $5 from $4.50. A Neutral rating is retained, assuming a normalisation of growth to around 5%.
Read MoreVHT – Morgans rates the stock as Add
Morgans makes no changes to forecasts and retains its Add rating and $1.87 target price after Volpara Health Technologies reported a “solid” 2Q result.
Read MoreAPX – Citi rates the stock as Buy
Buy rating and $17.10 target retained.
Read MoreRMD – Credit Suisse rates the stock as Outperform
The analyst thinks recent share underperformance provides significant valuation upside. The $44 target price and Outperform rating are unchanged.
Read MoreAMI – Macquarie rates the stock as Outperform
Outperform maintained. Target rises to $0.55 from $0.50.
Read MoreVEA – UBS rates the stock as Buy
UBS maintains a Buy rating, expecting the business will benefit from rising demand for fuel as travel restrictions ease. Target is raised to $2.50 from $2.45.
Read MoreTCL – Morgans rates the stock as Add
Target price eases -3c to $14.79 from $14.82. Add rating retained to reflect a potential total shareholder return of 10% including a 2.5% cash yield, with quarterly CPI increases a potential catalyst.
Read MoreWES – Credit Suisse rates the stock as Neutral
The Neutral rating is retained. Target is raised to $60.38 from $59.91.
Read MoreHMC – Credit Suisse rates the stock as Neutral
The broker raises the target to $7.53 from $5.87 and retains a Neutral rating.
Read MoreZ1P – UBS rates the stock as Sell
UBS retains a Sell rating and $5.40 target.
Read MorePPT – Citi rates the stock as Neutral
Target price lifts to $40.40 from $39.40. Neutral rating retained.
Read More29M – Macquarie rates the stock as Outperform
Target falls to $3.30 from $3.60, Outperform retained.
Read MoreILU – Citi rates the stock as Neutral
The strong quarterly report has triggered (noticeable) upgrades to forecasts. Neutral with a target price of $10.00.
Read MoreALX – Macquarie rates the stock as Neutral
The broker maintains a Neutral rating given the French elections are looming and the main driver of the share price will be the extension of asset life. Target price is steady at $6.52.
Read MoreBPT – Morgans rates the stock as Add
The broker retains its Add rating and $1.71 target and believes the negative share price reaction provides a good share entry point.
Read MoreANZ – Credit Suisse rates the stock as Neutral
Credit Suisse is wary of being too negative on the bank given its sharp discount to the sector. Neutral rating and $28.50 target retained.
Read MoreABP – Credit Suisse rates the stock as Neutral
The broker retains a Neutral rating and raises the target to $3.48 from $3.36.
Read MoreCQR – Credit Suisse rates the stock as Outperform
Charter Hall is the broker’s preferred exposure in the sector as the reopening thematic gains traction. Target price rises to $4.28 from $4.03. Outperform rating retained.
Read MoreBAP – Macquarie rates the stock as Outperform
Macquarie lifts its FY22 and FY23 EPS forecasts by 3% and raises its target price by the same percentage to $8.80 from $8.55.The Outperform rating is unchanged.
Read MoreALL – UBS rates the stock as Buy
Buy rating retained. Target is raised to $55.00 from $44.40.
Read MoreALL – Credit Suisse rates the stock as Outperform
The Outperform rating and target price of $5.30 are retained.
Read MoreCVN – Macquarie rates the stock as Neutral
The broker retains a Neutral rating and $0.33 target.
Read MoreAWC – Credit Suisse rates the stock as Neutral
Credit Suisse does not recommend chasing the stock at the current price and downgrades to Neutral from Outperform. Target is $1.90.
Read MoreTWE – Morgans rates the stock as Add
The Add rating is maintained and the target eases to $13.90 from $14.01.
Read MoreHUB – Citi rates the stock as Buy
Buy rating maintained. Target rises to $35.76 from $32.00.
Read MoreS32 – Morgans rates the stock as Hold
The broker retains its Hold rating and the target price is adjusted to $3.74 from $3.65.
Read MoreHUB – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price increases to $36.50 from $34.00.
Read MoreAUB – Macquarie rates the stock as Outperform
The broker retains Outperform and a $25.52 target.
Read MoreAST – Morgans rates the stock as Hold
Morgans maintains its Hold rating, with both Brookfield and APA Group ((APA)) bidding for the business. The target price of $2.50 is retained, which is in-line with the all-cash offer.
Read More
